Omeros Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 3O8.F | SNDX | AGMB | ODTX | MAZE | TRXB | |
|---|---|---|---|---|---|---|
| Market cap | 1.15B | 940.80M | 337.35M | 937.14M | 1.85B | 371.89M |
| P/E (TTM) | 15.2 | — | — | — | — | — |
| Forward P/E | -12.3 | -14.4 | -3.4 | -4.5 | -10.5 | -7.0 |
| Price/book | -25.2 | -54.7 | 2.7 | 2.5 | 4.1 | -0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +172.12% | −28.86% | −53.24% | +18.76% | +12.66% | −1.93% |
| Today | −2.15% | −26.87% | 0.00% | −9.60% | +3.50% | −1.31% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 3O8.F news ›Omeros Corporation $OMER Position Decreased by NFSG Corp
Check Out Our Latest Research Report on Omeros Shares of Omeros stock opened at $16.20 on Monday. The business has a 50-day moving average of $18.41 and a 200 day moving average of $13.89. Omeros Corporation has a 12 month low of $6.24 and…
Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16
Shares of Omeros Corp (OMER) slumped 15% on Friday after a European Medicines Agency committee upheld a negative opinion on its drug for a serious post-transplant condition, though H.C. Wainwright dismissed the selloff as overdone. The…
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros is commercializing YARTEMLEA with its own field force in the U.S. market and plans to license commercialization rights to a third party in the European Union (EU) if EU marketing authorization is granted. Due to increasing demand…
Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
Omeros Corporation (OMER) was on investors’ radar on Friday after the European Medicines Agency (EMA) issued a negative opinion on the marketing application for its treatment of stem cell transplant-associated complications, marking a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- tradingview.com2
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.